Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 2016 International Prostate Cancer Update (IPCU) Slides
Transcript
Grand Rounds in Urology Best Practice and Leading Edge Knowledge for the Treatment of Urologic Disease http://www.grandroundsinurology.com 2016 International Prostate Cancer Update (IPCU) Slides Author : E. David Crawford, MD Categories : Prevention and Screening, Prostate Cancer Date : January, 2016 To view presentation slides, please click the individual titles within each session. Session I: Prevention, Screening, And Genomic Markers Chair: Alan W. Partin, MD, PhD Prostate Cancer Screening: What We’ve Learned and Where We Should Go Gerald L. Andriole, Jr., MD Early Detection and Family Practice Matt T. Rosenberg, MD When to Biopsy: The Role for PSA and Novel Biomarkers Stacy Loeb, MD Soy Isoflavones in Prostate Cancer Prevention, Treatment and Survivorship Omer Kucuk, MD What Are Currently the Best Decision Markers for Biopsy and Re-Biopsy of the Prostate? E. David Crawford, MD Progress in Prostate Cancer Grading 1/4 Grand Rounds in Urology Best Practice and Leading Edge Knowledge for the Treatment of Urologic Disease http://www.grandroundsinurology.com M. Scott Lucia, MD Targeted Prostate Cancer Screening: Role of Germline Genetic Testing A. Karim Kader, MD, PhD Session II: Localized Disease Chair: James A. Eastham, MD The Role of Multi-Parametric MRI: Implications and Implementation Nelson N. Stone, MD Active Surveillance: Update After 20 Years Alan W. Partin, MD, PhD Radical Prostatectomy: Management of Primary From Localized to Oligometastatic Diseases James A. Eastham, MD Radiologic Evaluation on Accurate Staging Phillip J. Koo, MD Prostate Biopsies and Targeted Therapy Nelson N. Stone, MD Radiation Therapy Update David Raben, MD Strategies of Radiotherapy for Intermediate- to High-risk Prostate Cancer Daisaku Hirano, MD Session III: Advanced Disease Cardiovascular Complications of ADT: Reviewing Preclinical and Clinical Data and Introducing the RADICAL-PC Trial Jehonathan Pinthus, MD, PhD Neuroendocrine Prostate Cancer (NEPC): Are We Selecting For It With Our Current Androgen Nihilism? Jehonathan Pinthus, MD, PhD Agonists Versus Antagonists: Are There Differences? 2/4 Grand Rounds in Urology Best Practice and Leading Edge Knowledge for the Treatment of Urologic Disease http://www.grandroundsinurology.com Thomas E. Keane, MBBCh Updating the Concepts of Biosynthesis Inhibitors and Anti-Androgens Bertrand Tombal, MD, PhD Statins, Aspirin, and Metformin (S.A.M.): The Best “Natural” Pills to Discuss/Recommend for Patients Concerned About Prostate Cancer Mark A. Moyad, MD, MPH Technology Update for Imaging in Advanced Prostate Cancer: Are There Global Variations? Bertrand Tombal, MD, PhD Session IV: Advanced And Metastatic Disease Chair: Neal D. Shore, MD Integrating Chemotherapy Earlier in Advanced Disease Daniel P. Petrylak, MD Current and Future Opportunities Combining Radiation with Immunotherapy Steven E. Finkelstein, MD Intermittent Therapy: When To Start, or Restart, and the Role of Imaging Leonard G. Gomella, MD Session V: Advanced And Castration-Resistant Disease Chair: Daniel P. Petrylak, MD Hormone Replacement Therapy Update TBD Radiopharmaceuticals: Has There Been Progress? Neal D. Shore, MD Prostate Cancer Treatment: From Monotherapy to Sequencing Raoul S. Concepcion, MD The Future of Clinical Research in Private Practice Lawrence I. Karsh, MD 3/4 Grand Rounds in Urology Best Practice and Leading Edge Knowledge for the Treatment of Urologic Disease http://www.grandroundsinurology.com 4/4 Powered by TCPDF (www.tcpdf.org)
